Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.35 |
| ▸ | EP300 | Q09472 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905797 | 0.86 | BRD4 (0.42) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL20495558 | 0.85 | BRD4 (0.40) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16896809 | 0.84 | BRD4 (0.41) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18359550 | 0.84 | BRD4 (0.40) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18359525 | 0.83 | BRD4 (0.44) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16896824 | 0.82 | BRD4 (0.39) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16906139 | 0.82 | BRD4 (0.39) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18359595 | 0.82 | FFAR1 (0.42) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL18359576 | 0.81 | BRD4 (0.40) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL16896928 | 0.80 | BRD4 (0.40) | BRD4CYP3A4CYP2C9BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2018-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | BRD4 4/4885CYP3A4 1942/4885CYP2C9 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.